A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK 3008348 | GSK 3008348 is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for Integrin Antagonist 1 was 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-33-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19767. |  |
| GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for GSK 3008348 (hydrochloride) is 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-40-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19767A. | |
| GSK3117391 | GSK3117391 (ESM-HDAC391) is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ESM-HDAC391; CHR-5154; HDAC-IN-3. CAS No. 1018673-42-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19772. | |
| GSK3117391 | GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminated the phase 1 trial. Uses: Gsk3117391, a hdac inhibitor, was developed by gsk considering its potential effect in the treatment of arthritis and rheumatoid. Synonyms: GSK3117391; GSK-3117391; GSK 3117391; GSK3117391A; GSK-3117391A; GSK 3117391A; HDAC-IN-3; SCHEMBL15144242; AFDPFLDWOXXHQM-NRFANRHFSA-N; CS-5448; HY-19772; 121555-EP2295410A1. Grades: 95%. CAS No. 1018673-42-1. Molecular formula: C22H33N3O4. Mole weight: 403.52. |  |
| GSK3145095 | GSK3145095 is a RIP1 kinase inhibitor with an IC 50 of 6.3 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622849-43-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111946. | |
| GSK317354A | GSK317354A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) inhibitor,but no detailed information has been published yet. Synonyms: GSK317354A; GSK-317354A; GSK 317354A. 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1,4-dihydropyrimidine-5-carboxamide. Grades: 98%. CAS No. 874119-13-8. Molecular formula: C25H18F4N6O. Mole weight: 494.45. | |
| GSK321 | GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50=4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 stably decreased 2-hydroxyglutarate (2-HG) production in several different IDH1 mutant AML cells within a 2-3 week time frame ex vivo. Because of the allosteric nature of the interaction, GSK321 is able to inhibit multiple mutant forms of IDH1, which is consistent with our cell biological observations. Furthermore, GSK321 retains excellent potency in cells, since it does not compete with the tightly bound cofactor. Synonyms: (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; GSK321; GSK 321; GSK-321; BDBM195601. Grades: >98%. CAS No. 1816331-63-1. Molecular formula: C28H28FN5O3. Mole weight: 501.56. | |
| GSK329 | GSK329 is a highly potent and moderately selective TNNI3K inhibitor. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK329; GSK-329; GSK 329. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.24. Purity: >98%. IUPACName: N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Canonical SMILES: O=C(N)N(C1=CC(Cl)=C(OC2=NC=NC(NC)=C2)C(Cl)=C1)C3=CC=CC(C(F)(F)F)=C3. Product ID: ACM1268490125. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK 299423. |  |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 ( PRMT5 ) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-101563. | |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Synonyms: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK343 | GSK343 is a potent, selective inhibitor of EZH2 with cellular activity. GSK343 inhibits EZH2 with an IC50 of 4nM and is over 1000-fold selective for other HMTs except EZH1 (60-fold selectivity). GSK343 inhibits H3K27 methylation in HCC1806 cells with an IC50 of <200nM as measured by immunofluorescence. GSK343 exhibited limited effects on the growth of EOC cells in conventional two-dimensional (2D) culture. In contrast, GSK343 significantly suppressed the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which more closely mimics the tumor microenvironment in vivo. Notably, GSK343 induces apoptosis of EOC cells in 3D but not 2D culture. In addition, GSK343 significantly inhibited the invasion of EOC cells. Synonyms: GSK343; GSK-343; GSK 343. CAS No. 1346704-33-3. Molecular formula: C31H39N7O2. Mole weight: 541.7. | |
| GSK-345931A | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: 869499-38-7(sodium); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid. Grades: 98%. CAS No. 869534-13-4. Molecular formula: C22H20ClNO3. Mole weight: 381.86. | |
| GSK-345931A sodium | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: GSK-345931A sodium; GSK 345931A sodium; GSK345931A sodium; 869534-13-4(Free); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid sodium salt. Grades: 98%. CAS No. 869499-38-7. Molecular formula: C22H19ClNNaO3. Mole weight: 403.83. | |
| GSK3532795 | GSK3532795 (BMS-955176) is a potent, orally active, second-generation HIV-1 maturation inhibitor, with EC 50 s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMS-955176. CAS No. 1392312-45-6. Pack Sizes: 1 mg. Product ID: HY-112714. | |
| GSK-356278 | GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease. Uses: Huntington's disease; major depressive disorder. Synonyms: GSK-356278; GSK356278; GSK 356278; 5-(5-((2,4-dimethyl-5-thiazolyl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-n-(tetrahydro-2H-pyran-4-yl)-1H-Pyrazolo(3,4-b)pyridin-4-amine. Grades: 98%. CAS No. 720704-34-7. Molecular formula: C21H25N7O2S. Mole weight: 439.54. | |
| GSK360A | GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure. Group: Biochemicals. Alternative Names: N- [ [1- (2-Cyclopropylethyl) -6-fluoro-1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinyl] carbonyl] glycine; N- [ [1- (2-Cyclopropylethyl) -6-fluoro-4-hydroxy-2-oxo-1, 2-dihydro-3-quinolinyl] carbonyl] glycine. Grades: Highly Purified. CAS No. 931399-19-8. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| GSK369796 Dihydrochloride | SK369796, also known as N-tert-butylisoquine, shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. GSK369796 was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. Synonyms: 2-[(tert-Butylamino)methyl]-5-[(7-chloroquinolin-4-yl)amino]phenol Dihydrochloride; GSK369796 Dihydrochloride; GSK 369796; GSK-369796; GSK369796; N-tert-Butyl isoquine. CAS No. 1010411-21-8. Molecular formula: C20H24Cl3N3O. Mole weight: 428.78. | |
| GSK376501A | GSK376501A is a bio-active chemical compound used for the treatment of type 2 diabetes and hypercholesterolemia. It was developed by GlaxoSmithKline and was once in clinic phase 1, but now it has been terminated. Uses: Gsk376501a is used for the treatment of type 2 diabetes and hypercholesterolemia. Synonyms: GSK-376501A;GSK376501;GSK-376501;1-[[3,5-bis(2-methoxyethoxy)phenyl]methyl]-3-(4-tert-butylphenyl)indole-2-carboxylic acid;1H-Indole-2-carboxylic acid, 1-((3,5-bis(2-methoxyethoxy)phenyl)methyl)-3-(4-(1,1-dimethylethyl)phenyl)-. Grades: >98 %. CAS No. 1010412-80-2. Molecular formula: C32H37NO6. Mole weight: 531.64. | |
| GSK 3787 | GSK 3787. Group: Biochemicals. Grades: Purified. CAS No. 188591-46-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-3787 | GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties. Synonyms: GSK-3787; GSK3787; GSK 3787. CAS No. 188591-46-0. Molecular formula: C15H12ClF3N2O3S. Mole weight: 392.78059. | |
| GSK-3β inhibitor 11 | GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β ( GSK-3β ) inhibitor ( IC 50 =10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 536731-65-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148132. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β) , with an IC 50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1448990-73-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-141480. | |
| GSK3β inhibitor II | GSK3β inhibitor II is an inhibitor of GSK3&beta. GSK3β inhibitor II can be used for research of Alzheimers disease (AD) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 478482-75-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-14679. | |
| GSK3β Inhibitor II | GSK3β Inhibitor II is a potent and selective inhibitor of glycogen synthase kinase-3β (GSK3β) with an IC50 value of 390 nM. Synonyms: ?Glycogen Synthase Kinase 3β?? Inhibitor II; Tip-oxadiazole; 4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-pyridine; 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole. Grades: ≥95%. CAS No. 478482-75-6. Molecular formula: C14H10IN3OS. Mole weight: 395.2. | |
| GSK3β Inhibitor XI | GSK3β inhibitor XI is a cell-permeable, potent and ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK3β; Ki = 25 nM) which is selective for GSK3β over a panel of 79 commonly studied protein kinases. Synonyms: 3-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(2-pyrazinyl)-1H-pyrrole-2,5-dione. Grades: ≥98%. CAS No. 626604-39-5. Molecular formula: C18H15N5O3. Mole weight: 349.3. | |
| GSK3β Inhibitor XVIII | GSK3β inhibitor XVIII is a cell-permeable, potent and selective inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = 64 nM). Synonyms: [2-chloro-4-[[4-(2-thienyl)-2-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)-methanone. Grades: ≥98%. CAS No. 1139875-74-3. Molecular formula: C20H20ClN5OS. Mole weight: 413.9. | |
| GSK-3beta Inhibitor XXIV (2-Methyl-5- (3-[4- (methylsulfinyl) phenyl) -1-benzofuran-5-yl) -1, 3, 4-oxadiazole, Racemic) | An orally bioavailable and blood-brain-barrier permeable oxadiazolo-benzofuranyl phenyl sulfoxide compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b (IC50=35nM, 34 and 140nM for racemic, (S)-9b eutomer and (R)-9b distomer). The (S)-9b eutomer displays excellent selectivity (IC50 > 10uM) over Cdk1/2/5, Chk1, p38a, JNK1, MEKK1, IKKb, PKCth, CK1d, EGFR, ErbB2, Src, Lck, IR, Tie2, c-Kit, c-Met, VEGFR2, FGFR3 and PDGFRa/b, and lowers tau phosphorylation at GSK-3b-Thr205 in a CWS (cold water stress) mouse model (3mg/kg, p.o.). Group: Biochemicals. Grades: Highly Purified. CAS No. 1005201-24-0. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXV (GSK-3beta, N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine, 5-(4-Nitrophenyl)-N-(3-chloro-4-methyl)phenyl-1,3,4-oxadiazol-2-amine) | A blood brain barrier permeable oxadiazole compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b activity (IC50=17.1nM) with excellent selectivity over Cdk2 (22% inhibition at 10uM). Shown to elevate liver glycogen levels by ~3.5- and ~4.3-fold in C57BL/6N mice when dosed at 5 and 15mg/kg (i.p.) amounts. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClN?O?. US Biological Life Sciences. | Worldwide |
| GSK-3 beta Inhibitor XXVII (3-Amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide, HCl) | A cell-permeable pyridinyl pyrazinecarboxamide compound that acts as a highly potent, reversible, and ATP-competitive inhibitor of GSK-3b (Ki=4.9nM) with ~110-fold greater selectivity over Cdk2 (Ki=540nM). Shows only a trivial effect on the activities of 26-related kinases at much higher doses. Blocks GSK-3b-mediated phosphorylation of Ser396 in stably transfected 3T3 fibroblasts expressing four-repeat tau protein (IC50=76nM). Readily crosses blood-brain barrier and exhibits desirable bioavailability and aqueous solubility. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GSK-3beta Inhibitor XXVII, CESI (2-(3-chloro-4-hydroxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-3-hydroxy-6-methyl-4H-chromen-4-one) | A cell-permeable, 3-hydroxychromone derived compound that acts as a selective and reversible inhibitor of GSK-3beta (IC50 < 100nM). Shown to increase phosphorylation at Ser9. Does not show any inhibitory effect on a panel of 15 other protein kinases, including AMPK and Akt. By blocking GSK-3beta activity, it acts as a positive regulator of b-catenin signaling. Does not affect the viability or the growth rate of 3T3-L1 preadipocytes, however, it significantly reduces their differentiation into adipocytes ( 50 to 100nM). Exerts anti-adipogenic activity by down-regulating C/EBPa and PPARg. Shown to reduce adipocyte size and diminish weight gain in diet-induced obese mice without affecting their daily food intake. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??ClNO?S, Primary Target: GSK3b. US Biological Life Sciences. | Worldwide |
| GSK-3 inhibitor 1 | GSK-3 inhibitor 1 is a potent GSK-3 inhibitor. Grades: >98%. CAS No. 603272-51-1. Molecular formula: C22H17ClFN5O2. Mole weight: 437.85. | |
| GSK-3 inhibitor 3 | GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3 , with IC 50 s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimers disease model, with IC 50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2227279-84-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-154851. | |
| GSK-3 Inhibitor, AR-A014418, (N-[(4-Methoxyphenyl)methyl]-N-(5-nitro-2-thiazolyl)urea) | Cell-permeable. A selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104nm). Inhibition is competitive with respect to ATP (Ki = 38nm). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 =um) and over 26 other kinases. Inhibits b-amyloid-mediated neurodegeneration in hippocampal slices. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 2mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| GSK-3 Inhibitor IX ((2Z,3E)-6-Bromoindirubin-3-oxime) | A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3a/b (IC50=5nM). Its specificity has been tested against various Cdk's (IC50=83, 300, 320, and 10,000nM for Cdk5/p25, Cdk2/A, Cdk1/B, and Cdk4/D1, respectively) as well as many other commonly studied kinases (IC50≥10uM), including MAP kinases, PKA, PKC isoforms, PKG, CK, and IRTK. Inhibition of GSK by BIO has been shown to result in the activation of Wnt-signaling pathway and sustained pluripotency in human and murine ESCs (embryonic stem cells). Reported to maintain self-renewal in human and mouse embryonic stem cells. Also induces the differentiation of neonatal cardiomyocytes. Group: Biochemicals. Grades: Highly Purified. CAS No. 667463-62-9. Pack Sizes: 1mg, 10mg. US Biological Life Sciences. | Worldwide |
| GSK3 Inhibitor XIII | GSK3 Inhibitor XIII is a potent and ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3). Synonyms: Glycogen Synthase Kinase 3 Inhibitor XIII; 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-4-quinazolinamine. Grades: ≥98%. CAS No. 404828-08-6. Molecular formula: C18H19N5. Mole weight: 305.4. | |
| GSK3 Inhibitor XV | GSK3 inhibitor XV is a racemic mixture of (R)-GSK3 inhibitor XV and (S)-GSK3 inhibitor XV. (R)-GSK3 inhibitor XV inhibits glycogen synthase kinase (GSK) 3α and β with IC50 values of 0.35 and 0.55 nM respectively. (S)-GSK3 inhibitor XV is less potent than the (R)-GSK3 inhibitor XV. Synonyms: [11-bromo-9-hydroxypyrido[2, 3-a]pyrrolo[3, 4-c]carbazole-5, 7(1H, 6H)-dionato-κN1, κN12]carbonyl[(1, 2, 3, 4, 5-η)-1-(methoxycarbonyl)-2, 4-cyclopentadien-1-yl]-ruthenium. Grades: ≥98%. CAS No. 936112-69-5. Molecular formula: C25H14BrN3O6Ru. Mole weight: 633.40. | |
| GSK4027 | GSK4027 is a potent and selective inhibitor of p300/CBP-associated factor (PCAF)/general control nonderepressible 5 (GCN5) bromodomain (Ki = 1.4 nM; IC50 = 60 nM in a chromatin engagement assay). Synonyms: 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenyl-3-piperidinyl]amino]-3(2H)-pyridazinone. Grades: ≥95%. CAS No. 2079896-25-4. Molecular formula: C17H21BrN4O. Mole weight: 377.3. | |
| GSK4112 | GSK 4112, a kind of synthetic agonist of REV-ERBα, could suppress the expression of sorts of genes involved in gluconeogenesis. IC50: 0.4 μM (EC50). Uses: Gsk 4112 is a kind of synthetic agonist of rev-erbα and could suppress the expression of sorts of genes involved in gluconeogenesis. Synonyms: GSK4112; GSK 4112; GSK-4112. SR6452;CHEMBL1961795;1216744-19-2;MLS006010708;GTPL2903. Grades: 95%. CAS No. 1216744-19-2. Molecular formula: C18H21ClN2O4S. Mole weight: 396.89. | |
| GSK 4112 | GSK 4112. Group: Biochemicals. Grades: Purified. CAS No. 1216744-19-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively. Uses: Reprogramming, self-renewal. Synonyms: GSK 429286A; GSK-429286A. Grades: 0.98. CAS No. 864082-47-3. Molecular formula: C21H16F4N4O2. Mole weight: 432.37. | |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. Product Category: Inhibitors. Appearance: White to Beige Powder. CAS No. 929095-18-1. Molecular formula: C27H28N5O2F3S. Mole weight: 543.6. Purity: 0.96. Product ID: ACM929095181. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Synonyms: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.609. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. Product Category: Inhibitors. Appearance: White solid powder. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.6. Purity: >98%. IUPACName: (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide. Canonical SMILES: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C=NC4=CC=C(CN5CCN(C)CC5)C=C34)S1)N. Product ID: ACM929095181-2. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK 461364 analogue I | GSK 461364 analogue I is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM). Synonyms: GSK 461364 analogue I; GSK461364 analogue I; GSK-461364 analogue I; GSK579289A; GSK 579289A; GSK-579289A. Compound 25 [PMID 19237286]; 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide. Grades: 99%. CAS No. 929095-23-8. Molecular formula: C26H27ClN4O3S. Mole weight: 511.04. | |
| GSK 461364 analogue II | GSK 461364 analogue II is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 270 nM). Synonyms: GSK 461364 analogue II; GSK461364 analogue II; GSK-461364 analogue II; 5-[6- (1-methylpiperidin-4-yl) oxybenzimidazol-1-yl]-3-[ (1R) -1-[2- (trifluoromethyl) phenyl]ethoxy]thiophene-2-carboxamide. Grades: 99%. CAS No. 929095-22-7. Molecular formula: C27H27F3N4O3S. Mole weight: 544.59. | |
| GSK466317A | GSK466317A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK466317A; GSK-466317A; GSK 466317A. N-(7-chloro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide. Grades: 98%. CAS No. 864082-48-4. Molecular formula: C21H16ClF3N4O2. Mole weight: 448.83. | |
| GSK 4716 | GSK 4716 is a selective agonist of estrogen-related receptors ERRβ and ERRγ displaying selectivity over ERRα and the classical estrogen receptors. Activation of GSK 4716 regulates mitochondrial activity in skeletal muscle during exercise. Synonyms: GSK4716; GSK 4716; GSK-4716; 4-Hydroxy-2-[ (1E) -[4- (1-methylethyl) phenyl]methylene]hydrazide. Grades: ≥99% by HPLC. CAS No. 101574-65-6. Molecular formula: C17H18N2O2. Mole weight: 282.34. | |
| GSK 4716 | GSK 4716. Group: Biochemicals. Grades: Purified. CAS No. 101574-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK481 | GSK481 is a potent inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1 or RIP1; IC50 value 2.8 nM for inhibition of Ser166 autophosphorylation of hWT RIP1) with preference for RIP1 over 450 other kinases. Synonyms: GSK481; GSK-481; GSK 481. 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide. Grades: 98%. CAS No. 1622849-58-4. Molecular formula: C21H19N3O4. Mole weight: 377.39. | |
| GSK-484 | GSK-484 is a potent protein-arginine deiminase type-4 (PAD-4) inhibitor. Synonyms: GSK484; GSK 484. Grades: ≥98% by HPLC. CAS No. 1652629-23-6. Molecular formula: C27H31N5O3. Mole weight: 473.6. | |
| GSK-503 | GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different cancers. Synonyms: GSK503; GSK 503; GSK503. Grades: 98%. CAS No. 1346572-63-1. Molecular formula: C31H38N6O2. Mole weight: 526.67. | |
| GSK5182 | GSK5182 is a specific inverse agonist for estrogen-related receptor γ. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK5182; GSK 5182; GSK-5182. Product Category: Agonists. Appearance: Solid powder. CAS No. 877387-37-6. Molecular formula: C27H31NO3. Mole weight: 417.55. Purity: >98%. IUPACName: 4-[(Z)-1-[4-(2-dimethylaminoethoxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol. Canonical SMILES: OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CCCO)C=C1. Product ID: ACM877387376. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK525762 | GSK525762A, also known as I-BET-762 and GSK525762, is a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor GSK525762 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth. Synonyms: GSK525762; GSK525762; GSK525762; GSK525762A; GSK-525762A; GSK 525762A; I-BET-762; I-BET762; I-BET 762; molibresib. CAS No. 1260907-17-2. Molecular formula: C22H22ClN5O2. Mole weight: 423.9. | |
| GSK 525762A | GSK 525762A. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide; I-BET 762. Grades: Highly Purified. CAS No. 1260907-17-2. Pack Sizes: 5mg. Molecular Formula: C22H22ClN5O2, Molecular Weight: 423.9. US Biological Life Sciences. | Worldwide |
| GSK 525762A-d5 | GSK 525762A-d5. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide-d5; I-BET 762-d5. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C22H17D5ClN5O2, Molecular Weight: 428.93. US Biological Life Sciences. | Worldwide |
| GSK 525768A | GSK 525768A is a enantiomer analogue of GSK 525762A which is a BET family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to BET bromodomains. Uses: Gsk 525768a is a enantiomer analogue of gsk 525762a which is a bet family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to bet bromodomains. Synonyms: GSK 525768A; GSK525768A; GSK-525762A; CHEMBL2153435; SCHEMBL12966358; DTXSID50680634. Grades: 98%. CAS No. 1260530-25-3. Molecular formula: C22H22ClN5O2. Mole weight: 423.90. | |
| GSK547 | GSK547 is a highly selective and potent RIP1 (RIPK1) inhibitor which displays 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK963. Synonyms: RIP1i. Grades: ≥98%. CAS No. 2226735-55-1. Molecular formula: C20H18F2N6O. Mole weight: 396.39. | |
| GSK-5498A | GSK-5498A, a CRAC channel blocker, has been found to have effect in restraining pro-inflammatory cytokine. IC50: 1 uM. Uses: Gsk-5498a is a crac channel blocker that has been found to have effect in restraining pro-inflammatory cytokine. Synonyms: GSK-5498A; GSK5498A; GSK 5498A; 2,6-Difluoro-N-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)benzamide. Grades: 97%. CAS No. 1253186-49-0. Molecular formula: C18H11F6N3O. Mole weight: 399.29. | |
| GSK554418A | GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain. Uses: Chronic pain. Synonyms: GSK-554418A; GSK 554418A; GSK554418A. (4-((3-chlorophenyl)amino)-1-methyl-1H-pyrrolo(3,2-C)pyridin-7-yl)-4-morpholinyl- Methanone. Grades: 98%. CAS No. 871819-90-8. Molecular formula: C19H19ClN4O2. Mole weight: 370.84. | |
| GSK583 | GSK583 is a selective receptor-interacting serine/threonine-protein kinase 2 (RIP2 Kinase) inhibitor and the RIP2K binding IC50 is 5 nM. GSK583 can inhibit both TNF-α and IL-6 production with an IC50 value of 200 nM in an ex vivo human translational model. Synonyms: GSK583; GSK 583; GSK-583. 6 - (tert-Butylsulfonyl) - N - (5-fluoro - 1H - indazol-3-yl)quinolin-4-amine. Grades: 98%. CAS No. 1346547-00-9. Molecular formula: C20H19FN4O2S. Mole weight: 398.46. | |
| GSK591 | GSK591, also known as EPZ015866 and GSK3203591, is a chemical probe for PRMT5. In an in vitro biochemical assay, GSK591 potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50=11 nM. In Z-138 cells, GSK591 inhibits the symmetric arginine methylation of SmD3 with EC50=56 nM. Further, GSK591 is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases. (http://www.thesgc.org/chemical-probes/GSK59). Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK591; GSK-591; GSK 591; EPZ015866; EPZ-015866; EPZ 015866; GSK 3203591; GSK-3203591; GSK3203591. Product Category: Others. Appearance: Solid powder. CAS No. 1616391-87-7. Molecular formula: C22H28N4O2. Mole weight: 380.49. Purity: >98%. IUPACName: (S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide. Canonical SMILES: O=C(NC[C@H](O)CN1CCC(C=CC=C2)=C2C1)C3=CC(NC4CCC4)=NC=C3. Product ID: ACM1616391877. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK-598809. | |
| GSK5959 | GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 value of 80 nM. It exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. It is used at 10 μM final concentration in various in vitro assays. It disrupts chromatin binding of BRPF1 in a cellular assay by blocking the interaction of BRPF1 with histone H3 in vitro. Uses: Gsk-5959 disrupts chromatin binding of brpf1 in a cellular assay. Synonyms: N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide;GSK-5959; GSK 5959; GSK5959. Grades: >98%. CAS No. 901245-65-6. Molecular formula: C22H26N4O3. Mole weight: 394.47. | |
| GSK 5959 | GSK 5959. Group: Biochemicals. Grades: Purified. CAS No. 901245-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-598809 | GSK598809 is a selective Dopamine D3 receptor antagonist originated by GlaxoSmithKline. It may decrease the rewarding effects of contextual cues associated with drug intake preclinically and that may reduce drug craving in humans. No recent development for the treatment of Drug abuse. Eating disorders and Smoking withdrawal was reported. Uses: Drug abuse; eating disorders; smoking withdrawal. Synonyms: GSK-598809; GSK 598809; GSK598809; NII-Y5OZ63HC3V;5-(5-((3-((1S,5R)-1-(2-Fluoro-4-(trifluoromethyl)phenyl)-5-methyl-3-azabicyclo(3.1.0)hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole. Grades: 98%. CAS No. 1310803-30-5. Molecular formula: C23H25F4N5OS. Mole weight: 495.54. | |
| GSK621 | GSK621 is an activator of AMP-activated protein kinase (AMPK). GSK621 induces autophagy and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation. Synonyms: GSK-621; GSK 621. Grades: 98%. CAS No. 1346607-05-3. Molecular formula: C26H20ClN3O5. Mole weight: 489.91. | |
| GSK-626616 | GSK-626616 is a YAK3/DYRK3 kinase inhibitor. It is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Uses: Gsk-626616 is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Synonyms: GSK-626616; GSK 626616; GSK626616; (5Z)-2-(2,6-Dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolone;GSK626616;(5Z)-2-(2,6-dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazol-4-one. Grades: >98 %. CAS No. 1025821-33-3. Molecular formula: C18H10Cl2N4OS. Mole weight: 401.26. | |
| GSK650394 | GSK650394 is a competitive inhibitor that quantitatively blocks the effect of androgens on LNCaP cell growth. Synonyms: GSK650394; GSK-650394; GSK 650394. Grades: 0.98. CAS No. 890842-28-1. Molecular formula: C25H22N2O2. Mole weight: 382.45. | |
| GSK 650394 | GSK 650394 Inhibitor. Uses: Scientific use. Product Category: T2622. CAS No. 890842-28-1. |  |
| GSK 650394 | GSK 650394 is a novel SGK inhibitor with IC 50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication. Uses: Scientific research. Group: Signaling pathways. CAS No. 890842-28-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15192. | |
| GSK6853 | GSK6853 is a potent (pKd 9.5), soluble, cell active (20 nM), and highly selective inhibitor of the BRPF1 bromodomain with greater than 1600-fold selectivity over all other bromodomains tested. Synonyms: N-[1,3-dimethyl-6-[(2R)-2-methylpiperazin-1-yl]-2-oxobenzimidazol-5-yl]-2-methoxybenzamide; GSK6853; GSK-6853; GSK-6853. Grades: >98%. CAS No. 1910124-24-1. Molecular formula: C22H27N5O3. Mole weight: 409.49. | |
Our database is helping our users find suppliers everyday.
